Rhodium(III)-Catalyzed *ortho*-Alkylation of Phenoxy Substrates with Diazo Compounds via C–H Activation: A Case of Decarboxylative Pyrimidine/Pyridine Migratory Cyclization Rather than Removal of Pyrimidine/Pyridine Directing Group

Manjula Ravi, Srinivasarao Allu, and K. C. Kumara Swamy*®

School of Chemistry, University of Hyderabad, Hyderabad 500 046, Telangana, India

Supporting Information



ABSTRACT: An efficient Rh(III)-catalyzed *ortho*-alkylation of phenoxy substrates with diazo compounds has been achieved for the first time using pyrimidine or pyridine as the directing group. Furthermore, bis-alkylation has also been achieved using *para*-substituted phenoxypyrimidine and 3 mol equiv of the diazo ester. The *ortho*-alkylated derivatives of phenoxy products possessing the ester functionality undergo *decarboxylative pyrimidine/pyridine migratory cyclization* (rather than deprotection of pyrimidine/pyridine group) using 20% NaOEt in EtOH affording a novel class of 3-(pyrimidin-2(1H)-ylidene)benzofuran-2(3H)-ones and 6-methyl-3-(pyridin-2(1H)-ylidene)benzofuran-2(3H)-one. The *ortho*-alkylated phenoxypyridine possessing ester functionality also undergoes decarboxylative pyridine migratory cyclization using MeOTf/NaOMe in toluene providing 6-methyl-3-(1-methylpyridin-2(1H)-ylidene)benzofuran-2(3H)-one.

INTRODUCTION

Phenols are ubiquitous structural motifs found in a wide range of natural products, pharmaceuticals, polymers, and agrochemicals.¹ In addition to these, phenols and their derivatives (e.g., aryl-triflates, -pivalates -carbamates, and sulfamates) are widely used as coupling partners in cross-coupling reactions.² Given the synthetic and economic potential of the phenol/phenoxy derivatives, much recent attention has been devoted to functionalize C-H bonds on phenoxy substrates. Thus, during the past few years, phenols,³ siloxides/silanols,⁴ phenoxy esters,⁵ carbamates,⁶ and 2-phenoxypyridines⁷ have been successfully utilized as versatile substrates for C-H functionalization. In addition, 2-phenoxypyrimidines are also used as substrates for ortho-acetoxylation and arylation.⁸ Despite the fact that many C-H functionalization reactions are reported on phenoxy substrates, to the best of our knowledge, ortho-alkylation of phenoxy precursors using diazo compounds has not been reported so far. Recently, several research groups have described ortho-alkylation/annulation reactions using diazo compounds in the presence of rhodium(III),⁹ iridium(III),¹⁰ or cobalt(III)¹¹ catalysts. In continuation to our studies on C-H functionalization,¹² we describe herein a Rh(III)-catalyzed *ortho*-alkylation of phenoxy substrates using 2-phenoxypyrimidine/2-phenoxypyridine as substrates. Interestingly, while trying to remove the directing group, we observed a novel case of decarboxylative pyrimidine/pyridine migratory cyclization (*rather than deprotection*) furnishing 3-(pyrimidin-2(1H)-ylidene)benzofuran-2(3H)-ones, 6-methyl-3-(pyridin-2(1H)-ylidene)benzofuran-2(3H)-one and 6-methyl-3-(1-methylpyridin-2(1H)-ylidene)benzofuran-2(3H)-one. We believe that this observation is important since pyrimidine/pyridine groups are widely used removable directing groups with no reported case of such a rearrangement/migration.

RESULTS AND DISCUSSION

We began our studies by using 2-phenoxypyrimidine 1a and diethyl diazomalonate 2a as model substrates for the reaction. Pleasingly, we isolated the *ortho*-alkylated product 3a in 30% yield when we treated 2-phenoxypyrimidine 1a, with diethyl

Received: November 8, 2016 Published: February 9, 2017 diazomalonate **2a** in the presence of $[Cp*RhCl_2]_2$ (2.5 mol %), NaOAc (30 mol %) in MeOH solvent at 60 °C for 12 h (Table 1,

Table 1. Optimization Study for the [Rh]-CatalyzedAlkylation with Diazo Compounds a

\wedge			CO₂Et
Mo	N ₂ [Cp*RhC	l ₂] ₂ (2.5 mol %)	CO ₂ Et
we ~	N N 2a 60'	ve, solvent Me ⁰C, 12 h	
entry	additive	solvent	yield (%) ^b
1	NaOAc	MeOH	30
2	AgOAc	MeOH	51
3	Ag ₂ CO ₃	MeOH	23
4	AgOTf	MeOH	42
5	AgF ₂	MeOH	20
6	$AgBF_4$	MeOH	54
7	AgSbF ₆	MeOH	65
8	AgSbF ₆ /PivOH (20 mol %)	MeOH	78
9	PivOH	MeOH	46
10	AgSbF ₆ /PivOH (20 mol %)	EtOH	61
11	AgSbF ₆ /PivOH (20 mol %)	TFA	15
12	AgSbF ₆ /PivOH (20 mol %)	DCE	21
13	AgSbF ₆ /PivOH (20 mol %)	PEG	Trace
14	AgSbF ₆ /PivOH (20 mol %)	toluene	25 [°]
15	AgSbF ₆ /PivOH (20 mol %)	dioxane	40 ^c
16	AgSbF ₆ /PivOH (20 mol %)	tAmOH	52 ^c

^{*a*}Reaction conditions: **1a** (0.3 mmol), α -diazo ester **2a** (0.36 mmol), [Cp*RhCl₂]₂ (2.5 mol %), additive (10 mol %), solvent (3 mL), 60 °C (oil bath temperature). ^{*b*}Isolated yield. ^{*c*}At 110 °C.

entry 1). Encouraged by this, we screened various additives and solvents to get the optimal yield of the product **3a**. Among the additives screened (entries 2–7), AgSbF₆ enhanced yield of the product to 65%. After adding PivOH (20 mol %) as coadditive along with AgSbF₆, drastic improvement in the yield of the product (78%) was observed with complete consumption of the starting material, 2-phenoxypyrimidine **1a** (entry 8). However, the reaction using PivOH itself as additive, in the absence of AgSbF₆ led to decreased in the yield (46%) of the product (entry 9). A brief examination of solvents revealed that MeOH is a good solvent for this reaction (entries 10–16). On the basis of these, the optimal reaction conditions for the present reaction are 2-phenoxypyrimidine (1 equiv), *α*-diazo carbonyl compound (1.2 equiv), [Cp*RhCl₂]₂ (2.5 mol %), AgSbF₆ (10 mol %), PivOH (20 mol %) in MeOH solvent at 60 °C for 12 h.

After having the optimized reaction conditions in hand, the scope of the carbenoid functionalization was subsequently explored with respect to phenoxy precursors and diazocarbonyl compounds (Scheme 1). Initially, the unsubstituted 2-phenoxypyrimidine **1m** was tested under these conditions, but here we isolated mono- and bis-C-H functionalization products in an overall yield of 79% in the ratio 3:1, respectively. The reaction using substrates bearing electron donating groups (-OMe, -Me) or electron withdrawing groups (-F, -CF₃) proceeded smoothly affording the *ortho*-alkylated phenoxy derivatives in good yields. Bromo and chloro functional groups (cf. **1c**-**d**) were well tolerated, thus paving the way for further transformations. *ortho*-Substituted phenoxy precursors also underwent carbenoid coupling smoothly providing the alkylated derivatives **3h** and **3i** in good yields. In particular, substrate bearing 2-alkynyl

substituent (1j) was also compatible giving good yield (68%) of the alkylated product 3j. We were pleased to find that those bearing 2-naphthyl substituents at the α -position (1k and 1l) also worked well and the products 3k and 3l were obtained in 74% and 70% yields, respectively. But in the case of 1-naphthyl substituted precursor 1n, two regio-isomeric products (3n and 3n') were formed in equal ratio. We were able to separate both the isomers through column chromatography. This reaction is interesting in that it paves a way for the substituents was further investigated by using α -diazomalonates bearing Me and *i*-Pr substituents; in both the cases the *ortho*-alkylated products 3o and 3p were isolated in excellent yields.

We were also successful in achieving bis-alkylation in some cases by increasing the amount of diazomalonate to 3 mol equiv with respect to phenoxy substrates (Scheme 2). Thus, we have synthesized three bis-alkylated products 4a-4c in good yields.

Removal of the pyrimidine directing group from the orthoalkylated phenoxy pyrimidines (3a-p and 4a-c), can lead to free phenol derivatives, which are useful for further transformations. For this purpose, we conducted the reaction of 3a with 20% NaOEt in EtOH using DMSO solvent at 110 °C (Scheme 3). After careful examination of the product, we found that the novel decarboxylative rearranged product 5a involving pyrimidyl group migration was formed instead of free phenol derivative. The structure of 5a was confirmed by using X-ray crystallography (Figure S2) that clearly reveals an $NH \cdots O(C)$ type H-bonded dimer. This product seems to be the result of an unusual rearrangement. The generality of this rearrangement was examined by employing phenoxy derivatives (3b-g) and naphthalene derivatives 3k-l; in all the cases good to excellent yields of such decarboxylatively rearranged/cyclized products (5a-i) were isolated.¹³ We also isolated compounds A-B; although IR/HRMS data were consistent with these, we could not obtain sharp signals in the ${}^{1}\text{H}/{}^{13}\text{C}$ NMR spectra of these. We tried an alternative method for removing the pyrimidine directing group, by treating ortho-alkylated phenoxy pyrimidine 3a with MeOTf/toluene at 100 °C to form the corresponding pyridinium salt. Subsequently, the crude pyridinium salt was refluxed in Na/MeOH solution for 30 min gave the same decarboxylative rearranged product 5a in 64% yield; we did not observe any pyrimidine cleaved free phenol derivative.

In view of the importance of the 2-phenoxypyridine skeleton in pharmaceuticals,¹⁴ we have also checked the generality of our catalytic conditions by choosing 2-phenoxypyridine substrates. Thus the reaction of 2-pehoxypyridine substrates 6 with different diazo compounds 2 under the above catalytic conditions (Scheme 4) afforded good yields of the corresponding *ortho*alkylated 2-phenoxy pyridines (7a-c) that proves the generality of our catalytic system.

As our initial object was the synthesis of *ortho*-alkylated free phenol derivatives, we attempted some reactions for the removal of the pyridine directing group also. First, we tried the reaction of *ortho*-alkylated 2-phenoxy pyridine 7**a** with 20% NaOEt in DMSO solvent at 110 °C. Under these conditions, we obtained the decarboxylative rearranged product **8** (Scheme 5a). We also attempted a reaction for removing the pyridine directing group following a previously reported procedure.⁷ As shown in Scheme 5b, the reaction of *ortho*-alkylated 2-phenoxy pyridine 7**a** with MeOTf in toluene, and subsequent treatment with Na/MeOH under reflux conditions afforded only decarboxylative rearranged product **9**. The structure of the compound **9** was confirmed by Scheme 1. Scope of the Rh(III)-Catalyzed C-H Alkylation of Phenoxy Substrates with Diazomalonates^{*a,b*}



^{*a*}Reaction conditions: Phenoxy substrate 1 (0.3 mmol), diazo compound 2 (0.36 mmol), $[Cp*RhCl_2]_2$ (2.5 mol %), AgSbF₆ (10 mol %), PivOH (20 mol %), MeOH (3 mL) at 60 °C (oil bath temperature) for 12 h. ^{*b*}Isolated yields with column chromatography.

using X-ray crystallography. We did not obtain any free phenolic derivative under these conditions.

On the basis of the literature precedents on Rh(III)-catalyzed C–H functionalization of aromatic compounds using α -diazo compounds,^{9,12f} a plausible pathway is depicted in Scheme 6. Initially, pyrimidine nitrogen undergoes coordination to the active dicationic Rh(III) species [Rh(Cp*)][SbF₆]^{2–} followed by *ortho* C–H bond cleavage results in the formation of sixmembered rhodacycle intermediate I with the loss of one of the [SbF₆][–] as HSbF₆. Then, coordination of diazo compound to rhodium in intermediate I followed by the elimination of N₂ affords the metal-carbenoid intermediate III via the intermediate

II. Subsequently, migratory insertion of the carbene into the Rh– C bond gives intermediate **IV**, which upon protonation delivers the alkylated product by regenerating the active Rh(III) catalyst.

A plausible pathway for the decarboxylative pyrimidine migratory cyclization product **5a** is shown in Scheme 7. Initially, sodium ethoxide abstracts a proton from *ortho*-alkylated phenoxy precursor **V** which is followed by migration of pyrimidine group leading to the anion **VI**. Elimination of ethoxide (possibly as ethanol) followed by base hydrolysis and elimination of CO_2 results in **5a** via **VII** and **VIII**. A similar reaction sequence may be operative in the formation of compounds **8–9**.

Scheme 2. Scope of the Rh(III)-Catalyzed Double C-H Alkylation of Phenoxy Precursors with Diazomalonate (2a)^{*a,b*}



^{*a*}Reaction conditions: Substrate 1 (0.3 mmol), diazo compound 2a (0.9 mmol), [Cp*RhCl₂]₂ (2.5 mol %), AgSbF₆ (10 mol %), PivOH (20 mol %), MeOH (3 mL) at 60 °C (oil bath temperature) for 12 h. ^{*b*}Isolated yields after column chromatography.





^aReaction conditions: *ortho*-alkylated phenoxypyrimidine 3 (0.15 mmol), 20% NaOEt in EtOH (20 mol %), DMSO (2 mL) at 110 °C (oil bath temperature) for 3 h. Isolated yields after column chromatography.



CONCLUSIONS

In summary, we have developed the first Rh(III)-catalyzed *ortho*alkylation of phenoxy derivatives with α -diazo esters using 2phenoxypyrimidines/pyridines as substrates. The salient features of this catalytic system include mild catalytic conditions, large functional group compatibility, high product yields, and environmentally benign N_2 gas as the sole byproduct. More interestingly, we have also discovered a new decarboxylative pyrimidine migrated cyclization products in our attempt to remove (deprotect) the pyrimidine directing group. We believe that possibility of this type of reaction should be borne in mind Scheme 4. Scope of the Rh(III)-Catalyzed C-H Alkylation of 2-Phenoxypyridines with Diazo Compounds^{*a*,*b*}



^{*a*}Reaction conditions: Phenoxypyridine **6** (0.3 mmol), diazo compound **2** (0.36 mmol), $[Cp*RhCl_2]_2$ (2.5 mol %), AgSbF₆ (10 mol %), PivOH (20 mol %), MeOH (3 mL) at 60 °C (oil bath temperature) for 12 h. ^{*b*}Isolated yields after column chromatography.

2359





^aReaction conditions: *ortho*-alkylated phenoxypyridine 7a (0.50 mmol), MeOTf (0.88 mmol) PhMe (20 mL) at 100 °C (oil bath temperature) for 3 h, Na (12 mmol), MeOH (20 mL) at 80 °C for 30 min. Isolated yields after column chromatography.

while using the pyrimidine directing group that is widely used in C–H functionalization reactions.

EXPERIMENTAL SECTION

General Methods. Chemicals were purified when required according to standard procedures.¹⁵ All reactions, unless stated otherwise, were performed in a dry nitrogen atmosphere. ¹H and ¹³C NMR spectra were recorded using 5 mm tubes on 400 MHz NMR spectrometer with field strengths 400 and 100 MHz, respectively or on 500 MHz NMR spectrometer with field strengths 500 and 125 MHz, respectively in CDCl₃/DMSO-*d*₆ solution with shifts referenced to SiMe₄ ($\delta = 0$). All *J* values are in Hz. Infrared spectra were recorded neat or by using KBr pellets on a FT/IR spectrometer. Melting points were determined by using a local hot-stage melting point apparatus and are uncorrected. For TLC, glass micro slides were coated with silica-gel-GF₂₅₄ (mesh size 75 μ) and spots were identified using iodine or UV chamber as appropriate. For column chromatography, silica gel of 100–200 mesh size was used. Mass spectra were recorded using HRMS (ESI-TOF analyzer) equipment. X-ray data were collected at 298 K using Mo

Scheme 6. Plausible Pathway for the *ortho*-C–H Functionalization of Phenoxy Substrates



K α (λ = 0.710 73 Å) radiation. Structures were solved and refined using standard methods.¹⁶ CCDC nos. 1511133–1511134 and 1525099.

I. Synthesis of Precursors. All the 2-phenoxypyrimdine,^{7a} 2-phenoxypyridine,^{7b} and diazo substrates¹⁷ were synthesized by following the known procedures. Among these, 2-((6-bromonaph-thalen-2-yl)oxy)pyrimidine precursor **11** is new.

Compound **11**. Yield 1.96 g (82%, white solid): mp 94–98 °C; IR (KBr, cm⁻¹) 2953, 1562, 1397, 1299, 1237, 1195, 1139, 968, 891, 632 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 8.60 (s, 1H), 8.04 (s, 1H), 7.83 (d, *J* = 9.0 Hz, 1H), 7.89 (s, 1H), 7.70 (d, *J* = 8.5 Hz, 1H), 7.65 (s, 1H), 7.58 (d, *J* = 8.5 Hz, 1H), 7.39 (dd, *J* = 9.0 and 8.5 Hz, 1H), 7.08 (dd, *J* = 7.0 and 4.5 Hz, 1H); ¹³CNMR (100 MHz, CDCl₃) δ 165.3, 159.8, 150.8, 132.5, 132.3, 129.9, 129.9, 129.3, 128.7, 122.7, 119.4, 118.3, 116.4; HRMS (ESI) calcd for C₁₄H₉BrN₂O [M⁺ + H] *m*/*z* 300.9976 and 302.9956, found 300.9976 and 302.9956.

Scheme 7. Plausible Reaction Pathway for Migratory Cyclization



Phenoxy Precursors with Diazo Compounds. A mixture of phenoxypyrimidine/pyridine (0.3 mmol), diazo compound (0.36 mmol), $[Cp*RhCl_2]_2$ (2.5 mol %), $AgSbF_6$ (10 mol %) and PivOH (20 mol %)) was taken in a Schlenk tube [under ambient conditions; no inert atmosphere needed]. To this, MeOH (3 mL) was added and the contents stirred at 60 °C (oil bath temperature) for 12 h. After cooling to rt, the reaction mixture was extracted with DCM (3 × 20 mL). The combined organic phase was washed with brine solution (20 mL), dried over anh. Na₂SO₄ and concentrated in vacuo. The crude product was purified by column chromatography on silica gel using *n*-hexane-EtOAc (4:1) mixture as the eluent.

iii.a. General Procedure for the Synthesis of Migratory Cyclization Products from ortho-Alkylated Phenoxypyrimidines/Phenoxypyridines. A mixture of ortho-alkylated phenoxypyrimidine [or 7a] (0.15 mmol) and 20% NaOEt in EtOH (20 mol %) in DMSO (2 mL) was stirred for 3 h at 110 °C (oil bath temperature), then cooled and 2 N HCl (10 mL) was added. This was diluted with EtOAc $(3 \times 10 \text{ mL})$ and washed with brine solution (20 mL), dried over anh. Na₂SO₄ and concentrated in vacuo. The crude product was purified by column chromatography on silica gel using n-hexane-EtOAc (2:3) mixture as the eluent. We have tried an alternative method for removing the pyrimidine directing group by treating ortho-alkylated phenoxy pyrimidine 3a with MeOTf/toluene at 100 °C. Subsequently, this mixture was heated under reflux in Na/MeOH solution for 30 min to give the same decarboxylative rearranged product 5a. But the yield was better from the first method using NaOEt. We also tried the removal of pyrimidine directing group by treating compound 3a with N2H4/TFA in EtOH at 140 °C,¹⁸ but did not observe any product formation. We also conducted the reaction of compound 3a with Et₃SiH in TFA at 50 °C for 2 h, followed by the treatment with N_2H_4 /AcOH in MeOH at rt for 12-24 h.¹⁹ In this case also, there was no reaction.

iii.b. General Procedure for the Synthesis of Migratory Cyclization Products from *ortho*-Alkylated Phenoxypyridines. A mixture of *ortho*-alkylated phenoxypyridine (0.50 mmol) in 20 mL toluene and added MeOTf (0.88 mmol) under N₂ was stirred for 2 h at 100 °C (oil bath temperature). Then the reaction mixture was cooled, and solvent removed by evaporation. The residue was dissolved in dry methanol (5 mL). To this, NaOMe (12 mmol Na in 15 mL of methanol) under N₂ was added, the mixture was heated at 80 °C for 30 min, then cooled and solvent was removed by evaporation. The resulting mixture was extracted with DCM (3 × 10 mL) and washed with brine solution (20 mL), dried over anh. Na₂SO₄ and concentrated in vacuo. The product was purified by column chromatography on silica gel using *n*-hexane-EtOAc (3:2) mixture as the eluent.

Compound **3a**. Yield 0.080 g (78%, white solid); mp 80–84 °C; IR (KBr) 3052, 2975, 1731, 1567, 1408, 1304, 1145, 1041, 811, 729 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 8.57 (d, *J* = 4.8 Hz, 2H), 7.53 (d, *J* = 8.0 Hz, 1H), 7.14 (d, *J* = 7.2 Hz, 1H), 7.06 (t, *J* = 4.8 Hz, 1H), 7.01 (s, 1H), 4.93(s, 1H), 4.20–4.10 (m, 4H), 2.39 (s, 3H), 1.20 (t, *J* = 7.2 Hz, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 167.9, 165.2, 159.7, 150.5, 139.8, 130.2,

127.0, 122.8₃, 122.7₅, 116.3, 61.7, 51.0, 21.2, 13.9; HRMS (ESI) calcd for $C_{18}H_{21}N_2O_5$ [M⁺ + H] m/z 345.1450, found 345.1449.

Compound **3b**. Yield 0.079 g (73%, gummy liquid); IR (neat) 3068, 2981, 1742, 1573, 1501, 1408, 1030, 816, 745 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 8.57 (d, *J* = 4.5 Hz, 2H), 7.56 (d, *J* = 8.5 Hz, 1H), 7.07 (t, *J* ~ 4.8 Hz, 1H), 6.89 (dd, *J* = 8.5 and 2.5 Hz, 1H), 6.74 (d, *J* = 3.0 Hz, 1H), 4.88 (s, 1H), 4.19–4.10 (m, 4H), 3.80 (s, 3H), 1.19 (t, *J* ~ 7.3 Hz, 6H); ¹³C NMR (125 MHz, CDCl₃) δ 168.0, 165.1, 160.4, 159.8, 151.5, 131.2, 117.9, 116.5, 112.1, 108.1, 61.7, 55.5, 50.7, 14.0; HRMS (ESI) calcd for C₁₈H₂₁N₂O₆ [M⁺ + H] *m*/*z* 361.1400, found 361.1401.

Compound **3c.** Yield 0.087 g (71%, white solid); mp 74–78 °C; IR (KBr) 3063, 2975, 1748, 1567, 1403, 1299, 1036, 921, 734 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 8.58 (d, *J* = 4.8 Hz, 2H), 7.55 (d, *J* = 8.4 Hz, 1H), 7.46 (dd, *J* = 8.4 and 1.6 Hz, 1H), 7.39 (d, *J* = 2.0 Hz, 1H), 7.10 (t, *J* ~ 4.8 Hz, 1H), 4.95 (s, 1H), 4.21–4.12 (m, 4H), 1.20 (t, *J* = 7.2 Hz, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 167.4, 164.8, 159.9, 151.2, 131.8, 129.2, 125.9, 122.4, 116.9, 62.0, 51.0, 14.0; HRMS (ESI) calcd for C₁₇H₁₇BrN₂O₃Na [M⁺ + Na] and [M⁺ + Na + 2] *m/z* 431.0219 and 433.0198, found 431.0217 and 433.0197.

Compound **3d**. Yield 0.088 g (81%, white solid); mp 68–72 °C; IR (KBr) 3057, 2992, 1748, 1573, 1403, 1304, 1025, 926, 729 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 8.59 (d, *J* = 4.8 Hz, 2H), 7.61 (d, *J* = 8.4 Hz, 1H), 7.31 (d, *J* = 8.4 Hz, 1H), 7.24 (s, 1H), 7.11 (t, *J* ~ 4.6 Hz, 1H), 4.96 (s, 1H), 4.21–4.12 (m, 4H), 1.21 (t, *J* = 7.2 Hz, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 167.4, 164.7, 159.8, 151.1, 134.6, 131.5, 126.3, 124.5, 122.9, 116.8, 62.0, 50.8, 13.9; HRMS (ESI) calcd for C₁₇H₁₈ClN₂O₅ [M⁺ + H] and [M⁺ + H + 2] *m*/*z* 365.0905 and 367.0875, found 365.0904 and 367.0887.

Compound **3e**. Yield 0.075 g (72%, gummy liquid); IR (neat) 2986, 1753, 1573, 1474, 1419, 1238, 1096, 789 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 8.68 (d, *J* = 4.8 Hz, 2H), 7.37–7.31 (m, 1H), 7.17 (t, *J* ~ 5.0 Hz, 1H), 7.09 (d, *J* = 8.4 Hz, 1H), 7.05–7.00 (m, 1H), 5.65 (s, 1H), 4.29–4.21 (m, 4H), 1.33 (t, *J* = 7.2 Hz, 3H), 1.24 (t, *J* ~ 7.0 Hz, 3H); ¹³C NMR (100 MHz) δ 169.6, 166.2, 161.3 (d, *J*_(C-F) = 247.5 Hz), 157.2, 152.8, 150.2 (d, *J*_(C-F) = 6.6 Hz), 129.2 (d, *J*_(C-F) = 10.1 Hz), 119.3, 118.4 (d, *J*_(C-F) = 3.3 Hz), 118.2, 118.1, 113.3 (d, *J*_(C-F) = 22.4 Hz), 64.9, 61.7, 51.1, 14.2, 14.0; HRMS (ESI) calcd for C₁₇H₁₈FN₂O₅ [M⁺ + H] *m*/*z* 349.1200, found 349.1199.

Compound **3f**. Yield 0.094 g (69%, gummy liquid); IR (neat) 2982, 1732, 1567, 1479, 1407, 1391, 1293, 1216, 1154, 1030, 911, 844, 808 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 8.57 (d, *J* = 4.5 Hz, 2H), 7.64 (d, *J* = 8.0 Hz, 1H), 7.55 (s, 1H), 7.38 (d, *J* = 8.5 Hz 1H), 7.09 (t, *J* = 5.0 Hz, 1H), 4.93 (s, 1H), 4.19–4.10 (m, 4H), 1.19 (t, *J* = 7.0 Hz, 6H); ¹³C NMR (125 MHz, CDCl₃) δ 167.3, 164.8, 159.9, 151.0, 135.1, 132.0, 131.6, 125.8, 116.8, 93.6, 62.0, 51.0, 14.0; HRMS (ESI) calcd for $C_{17}H_{18}IN_2O_5$ [M⁺ + H] *m/z* 457.0261, found 457.0260.

Compound **3***g*. Yield 0.078 g (65%, gummy liquid); IR (neat) 2986, 1734, 1562, 1408, 1299, 1041, 942, 767 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 8.58 (d, *J* = 5.0 Hz, 2H), 7.80 (d, *J* = 8.5 Hz, 1H), 7.58 (d, *J* = 8.5 Hz, 1H), 7.49 (s, 1H), 7.12 (t, *J* ~ 4.8 Hz, 1H), 5.04 (s, 1H), 4.22–4.13 (m, 4H), 1.21 (t, *J* = 7.0 Hz, 6H); ¹³C NMR (125 MHz, CDCl₃) δ 167.2, 164.8, 159.9, 150.9, 131.7 (qrt, *J*_(C-F) = 33.2 Hz), 131.4, 129.8,

2360

The Journal of Organic Chemistry

124.6, 122.6 (qrt, $J_{(C-F)} \sim 4.0$ Hz), 122.4, 119.9 (qrt, $J_{(C-F)} \sim 3.6$ Hz), 117.0, 62.2, 51.2, 14.0; HRMS (ESI) calcd for $C_{18}H_{18}F_3N_2O_5$ [M⁺ + H] m/z 399.1169, found 399.1165.

Compound **3h**. Yield 0.074 g (72%, gummy liquid); IR (neat) 2981, 1731, 1573, 1468, 1403, 1304, 1041, 899, 762 cm⁻¹;¹H NMR (400 MHz, CDCl₃) δ 8.57 (d, *J* = 4.8 Hz, 2H), 7.48 (dd, *J* ~ 7.4 Hz, 1H), 7.29–7.24 (m, 2H), 7.05 (t, *J* ~ 4.8 Hz, 1H), 4.94 (s, 1H), 4.19–4.09 (m, 4H), 2.15 (s, 3H), 1.19 (t, *J* ~ 7.4 Hz, 6H);¹³C NMR (100 MHz, CDCl₃) δ 167.9, 164.7, 159.9, 149.3, 131.3, 131.2, 128.1, 126.2, 126.1, 116.2, 61.8, 51.4, 16.8, 14.0; HRMS (ESI) calcd for $C_{18}H_{20}N_2O_3Na$ [M⁺ + Na] *m*/*z* 367.1270, found 367.1274.

Compound 3i. Yield 0.076 g (71%, white solid); mp 76–80 °C; IR(KBr) 3046, 2992, 1731, 1567, 1408, 1310, 1255, 1030, 740 cm⁻¹; ¹HNMR (400 MHz,CDCl₃) δ 8.56 (d, *J* = 4.8 Hz, 2H), 7.27 (s, 1H), 7.09 (s, 1H), 7.04 (t, *J* ~ 4.8 Hz, 1H), 4.89 (s, 1H), 4.19–4.08 (m, 4H), 2.37 (s, 3H), 2.11 (s, 3H), 1.19 (t, *J* ~ 7.0 Hz, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 167.9, 164.8, 159.9, 147.0, 135.5, 132.1, 130.7, 128.4, 125.6, 116.1, 61.7, 51.3, 21.1, 16.6, 14.0; HRMS (ESI) calcd for C₁₉H₂₂N₂O₅Na [M⁺ + Na] *m/z* 381.1427, found 381.1428.

Compound 3j. Yield 0.088 g (68%, gummy liquid); IR (neat) 3052, 2975, 1759, 1731, 1578, 1496, 1452, 1397, 1288, 1140, 1036, 899, 762 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 8.58 (d, *J* = 4.8 Hz, 2H), 7.67 (dd, *J* ~ 7.8 Hz and ~1.4, 1H), 7.60 (dd, *J* = 7.6 Hz and 1.6, 1H), 7.33 (t, *J* ~ 7.8 Hz, 1H), 7.29–7.24 (m, 3H), 7.22–7.19 (m, 2H), 7.04 (t, *J* = 4.8 Hz, 1H), 5.11 (s, 1H), 4.22–4.14 (m, 4H), 1.21 (t, *J* = 7.2 Hz, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 167.6, 165.0, 159.7, 151.7, 133.0, 131.5, 130.6, 128.5, 128.2, 126.8, 125.8, 122.8, 118.0, 116.4, 95.1, 84.6, 62.0, 51.2, 14.0; HRMS (ESI) calcd for C₂₅H₂₃N₂O₅ [M⁺ + H] *m/z* 431.1608, found 431.1605.

Compound **3k**. Yield 0.084 g (74%, white solid); mp 94–98 °C; IR (KBr) 3057, 2981, 1742, 1567, 1507, 1397, 1299, 1145, 1036, 921, 756 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 8.59 (d, J = 4.8 Hz, 2H), 8.13 (s, 1H), 7.92–7.90 (m, 1H), 7.81–7.79 (m, 1H), 7.68 (s, 1H), 7.51–7.49 (m, 2H), 7.08 (t, J = 4.8 Hz, 1H) 5.09 (s, 1H), 4.24–4.14 (m, 4H), 1.22 (t, $J \sim 7.0$ Hz, 6H);¹³C NMR (100 MHz, CDCl₃) δ 167.8, 165.4, 159.8, 148.6, 133.6, 131.4, 130.3, 128.3, 127.3, 127.0, 125.9, 125.3, 119.4, 116.5, 61.9, 51.8, 14.0; HRMS (ESI) calcd for C₂₁H₂₀N₂O₅Na [M⁺ + Na] m/z 403.1270, found 403.1276.

Compound 3I. Yield 0.096 g (70%, white solid); mp 84–88 °C; IR (KBr) 3046, 2981, 1742, 1578, 1501, 1408, 1370, 1299, 1025, 915, 800 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 8.58 (d, *J* = 4.8 Hz, 2H), 8.08 (s, 1H), 8.04 (s, 1H), 7.68–7.66 (m, 2H), 7.59–7.57 (m, 1H), 7.10 (t, *J* ~ 4.6 Hz, 1H), 5.07 (s, 1H), 4.24–4.14 (m, 4H), 1.22 (t, *J* = 7.2 Hz, 6H); ¹³C NMR (100 MHz, CDCl₃) δ 167.6, 165.2, 159.9, 148.9, 132.4, 132.1, 130.3₄, 130.2₆, 129.5, 129.0, 126.6, 119.9, 119.5, 116.7, 62.1, 51.7, 14.0; HRMS (ESI) calcd for C₂₁H₂₀BrN₂O₅ [M⁺ + H] and [M⁺ + H + 2] *m/z* 459.0556 and 461.0535, found 459.0558 and 461.0535.

Compound **3m**. Yield 0.059 g (60%, along with **3m**'; total 79%, white solid); mp 78–82 °C; IR (KBr) 3052, 2981, 1742, 1573, 1408, 1030, 910, 723 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 8.56 (d, *J* = 4.8 Hz, 2H), 7.65–7.63 (m, 1H), 7.41–7.32 (m, 2H), 7.20 (d, *J* = 8.4 Hz, 1H), 7.06 (t, *J* = 4.8 Hz, 1H), 5.00 (s, 1H), 4.18–4.10 (m, 4H), 1.19 (t, *J* = 7.2 Hz, 6H);¹³C NMR (100 MHz) δ 167.7, 165.1, 159.8, 150.7, 130.5, 129.4, 125.9, 125.8, 122.4, 116.5, 61.8, 51.3, 13.9; HRMS (ESI) calcd for C₁₇H₁₈N₂O₅Na [M⁺ + Na] *m*/*z* 353.1114, found 353.1118.

Compound **3m**'. Yield 0.019 g (19%, along with **3m**, total 79%, gummy liquid); IR (neat) 3068, 2975, 1726, 1573, 1414, 1052, 734, 701 cm⁻¹; ¹H NMR (500 MHz) δ 8.52 (d, *J* = 4.5 Hz, 2H), 7.66 (d, *J* = 8.0 Hz, 2H), 7.39 (d, *J* = 8.0 Hz, 1H), 7.06 (t, *J* = 5.0 Hz, 1H), 4.89 (s, 2H), 4.16–4.06 (m, 8H), 1.17 (t, *J* = 7.0 Hz, 12H); ¹³C NMR (125 MHz) δ 167.5, 164.9, 159.8, 148.9, 130.7, 126.6, 126.2, 116.7, 61.9, 51.5, 14.0; HRMS (ESI) calcd for C₂₄H₂₉N₂O₉ [M⁺ + H] *m/z* 489.1874, found 489.1864.

Compound **3n**. Yield 0.039 g (34%, combined yield along with **3n**' is 65%, white solid); mp 92–96 °C; IR (KBr) 3068, 2981,1737,1578,1414, 1299, 1030, 904, 805, 734 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 8.53 (d, *J* = 4.8 Hz, 2H), 7.92–7.75 (m, 4H), 7.54–7.45 (m, 2H), 7.05 (t, *J* = 4.8 Hz, 1H), 5.17 (s, 1H), 4.20–4.14 (m, 4H), 1.20 (t, *J* = 7.2 Hz, 6H); ¹³C NMR (100 MHz) δ 167.7, 165.5, 159.9, 146.6, 134.4, 128.0, 127.2, 126.7₁, 126.6₈, 126.6, 126.0, 122.4, 122.1, 116.4, 61.8, 51.4, 13.9; HRMS

(ESI) calcd for $C_{21}H_{21}N_2O_5 [M^+ + H] m/z$ 381.1451, found 381.1455. This compound was crystallized from dichloromethane.

Compound **3***n*'. Yield 0.034 g (31%, combined yield along with **3***n* is 65%, gummy liquid); IR (neat) 3052, 2986, 1759, 1573, 1425, 1364, 1101, 1025, 877, 740 cm⁻¹; ¹H NMR (400 MHz) δ 8.73 (d, *J* = 4.4 Hz, 2H), 7.88 (t, *J* ~ 5.0 Hz, 2H), 7.79 (d, *J* = 8.8 Hz, 1H), 7.72 (d, *J* = 8.8 Hz, 1H), 7.56–7.49 (m, 2H), 7.20–7.18 (m, 1H), 5.85 (s, 1H), 4.38–4.26 (m, 4H), 1.43 (t, *J* ~ 7.0 Hz, 3H), 1.27 (t, *J* = 7.2 Hz, 3H); ¹³C NMR (100 MHz) δ 170.2, 167.1, 157.3, 153.2, 144.8, 134.0, 127.9, 127.2, 126.9, 126.8, 126.6, 126.2, 125.4, 121.3, 119.4, 65.2, 61.6, 54.4, 14.2, 14.1; HRMS (ESI) calcd for $C_{21}H_{21}N_2O_5$ [M⁺ + H] *m*/*z* 381.1451, found 381.1454.

Compound **30**. Yield 0.069 g (73%, gummy liquid); IR (neat) 3140, 2948, 1742, 1622, 1567, 1507, 1402, 1140, 1019, 959, 882, 812 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 8.58 (s, 2H), 7.51 (d, *J* = 6.0 Hz, 1H), 7.16 (d, *J* = 3.6 Hz, 1H), 7.08–7.02 (m, 2H), 4.97 (s, 1H), 3.69 (s, 6H), 2.39 (s, 3H); ¹³C NMR (100 MHz) δ 168.3, 165.2, 159.8, 150.5, 140.1, 130.2, 127.1, 123.0, 122.5, 116.4, 52.8, 50.8, 21.3; HRMS(ESI) calcd for C₁₆H₁₇N₂O₅ [M⁺ + H] *m/z* 317.1138, found 317.1137.

Compound **3p**. Yield 0.104 g (93%, white solid); mp 84–88 °C; IR (neat) 2981, 2931, 1726, 1567, 1403, 1309, 1101, 800, 657 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 8.56 (dd, *J* = 4.8 and 1.2 Hz, 2H), 7.54 (d, *J* = 8.0 Hz, 1H), 7.14 (d, *J* = 8.0 Hz, 1H), 7.06–7.03 (m, 1H), 7.00 (s, 1H), 5.02–4.99 (m, 2H), 4.87 (s, 1H), 2.38 (s, 3H), 1.22 (d, *J* = 6.0 Hz, 6H); ¹³CNMR (100 MHz) δ 167.4, 165.3, 159.8, 157.3, 150.6, 139.7, 130.3, 126.9, 123.0, 122.8, 119.2, 116.3, 69.3, 51.2, 21.5₇, 21.5₅, 21.3; HRMS (ESI) calcd for C₂₀H₂₄N₂O₅Na [M⁺ + Na] *m*/*z* 395.1583, found 395.1582.

Compound 4a. Yield 0.102 g (68%, white solid); mp 78–82 °C; IR (KBr) 2981, 1737, 1578, 1485, 1403, 1370, 1036, 816, 740 cm⁻¹;¹H NMR(400 MHz, CDCl₃) δ 8.52 (d, *J* = 4.8 Hz, 2H), 7.45 (s, 2H), 7.05 (t, *J* = 4.8 Hz, 1H), 4.84 (s, 2H), 4.18–4.02 (m, 8H), 2.42 (s, 3H), 1.17 (t, *J* ~ 7.0 Hz, 12H);¹³C NMR (100 MHz, CDCl₃) δ 167.6, 164.9, 159.7, 146.6, 135.8, 131.1, 125.9, 116.5, 61.8, 51.3, 21.3, 13.9; HRMS (ESI) calcd for $C_{25}H_{31}N_2O_9$ [M⁺ + H] *m*/*z* 503.2030, found 503.2030.

Compound 4b. Yield 0.096 g (62%, gummy liquid); IR (neat) 3074, 2975, 1731, 1611, 1573, 1468, 1364, 1036, 899, 734 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 8.51 (d, *J* = 4.8 Hz, 2H), 7.19 (s, 2H), 7.04 (t, *J* = 4.8 Hz, 1H), 4.84 (s, 2H), 4.16–4.04 (m, 8H), 3.84 (s, 3H), 1.17 (t, *J* ~ 7.0 Hz, 12H); ¹³C NMR (100 MHz, CDCl₃) δ 167.4, 165.1, 159.8, 156.9, 142.6, 127.1, 116.6, 115.9, 61.8, 55.7, 51.5, 13.9; HRMS (ESI) calcd for C₂₅H₃₁N₂O₁₀ [M⁺ + H] *m*/*z* 519.1979, found 519.1980.

Compound 4c. Yield 0.104 g (64%, gummy liquid); IR (neat) 3074, 2964, 1731, 1578, 1414, 1299, 1030, 897, 734 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 8.53 (d, *J* = 4.8 Hz, 2H), 7.65 (s, 2H), 7.05 (t, *J* = 4.8 Hz, 1H), 4.87 (s, 2H), 4.17–4.07 (m, 8H), 1.38 (s, 9H), 1.19 (t, *J* ~ 7.0 Hz, 12H); ¹³C NMR (100 MHz) δ 167.7, 165.0, 159.8, 148.6, 146.6, 127.8, 125.5, 116.5, 61.8, 51.6, 34.8, 31.4, 14.0; HRMS (ESI) calcd for C₂₈H₃₇N₂O₉ [M⁺ + H] *m*/*z* 545.2499, found 545.2497.

Compound 5a. Yield 0.028 g (84%, red solid); mp 250–254 °C; IR (neat) 3096, 2915, 2855, 2367, 1814, 1677, 1600, 1430, 1315, 1183, 1090, 975, 800 cm⁻¹; ¹H NMR (400 MHz, DMSO- d_6) δ 12.79 (br s, 1H), 8.83 (br s, 1H), 8.32 (s, 1H), 7.66 (d, *J* = 7.6 Hz, 1H), 6.95 (s, 1H), 6.91 (d, *J* = 7.6 Hz, 1H), 6.80 (t, *J* ~ 5.6 Hz, 1H), 2.33 (s, 3H); ¹³C NMR (125 MHz, DMSO- d_6) δ 169.9, 153.7, 148.1, 131.2, 123.7, 123.2, 118.5, 109.4, 108.5, 81.9, 79.1, 21.1; HRMS (ESI) calcd for C₁₃H₁₁N₂O₂ [M⁺ + H] *m/z* 227.0820, found 227.0821. This compound was crystallized from acetonitrile.

Compound 5b. Yield 0.024 g (67%, red solid); mp 242–246 °C; IR (neat) 3107, 2915, 2860, 1808, 1688, 1605, 1496, 1309, 1205, 1112, 1002, 800 cm⁻¹; ¹H NMR (400 MHz, DMSO- d_6) δ 12.68 (br s, 1H), 8.65 (d, *J* = 4.8 Hz, 1H), 8.32 (s, 1H), 7.64 (d, *J* = 8.4 Hz, 1H), 6.80 (d, *J* = 2.0 Hz, 1H), 6.75 (d, *J* = 5.4 Hz, 1H), 6.69 (dd, *J* = 8.4 Hz, 1H), 3.74 (s, 3H); ¹³C NMR(125 MHz, DMSO- d_6) δ 169.9, 155.7, 153.3, 148.7, 119.2, 119.0, 108.4, 108.2, 96.3, 81.6, 79.1, 55.4; HRMS (ESI) calcd for C₁₃H₁₁N₂O₃ [M⁺ + H] *m*/*z* 243.0770, found 243.0768.

Compound 5c. Yield 0.035 g (79%, red solid); mp 252–256 °C; IR (neat) 2920, 2849, 2367, 1682, 1594, 1255, 1156, 1084, 811, 773 cm⁻¹; ¹H NMR (400 MHz, DMSO- d_6) δ 12.92 (br s, 1 H), 8.64 (s, 2H), 7.80–7.71 (m, 1H), 7.30–7.21 (m, 1H), 7.07–6.84 (m, 2H); ¹³C NMR (125

MHz, DMSO- d_6) δ 172.5, 169.6, 154.9, 148.8, 130.9, 125.8, 124.5, 120.3, 112.3, 110.2, 81.7; HRMS (ESI) calcd for C₁₂H₈BrN₂O₂ [M⁺ + H] and [M⁺ + H + 2] *m*/*z* 290.9769 and 292.9749, found 290.9764 and 292.9746.

Compound **5d**. (Purity ca. 95%¹³): Yield 0.028 g (77%, red solid); mp 260–264 °C; IR (neat) 3096, 2920, 2844, 1688, 1594, 1540, 1425, 1205, 1085, 970, 849, 778 cm⁻¹; ¹H NMR (400 MHz, DMSO- d_6) δ 12.94 (br s, 1H), 8.92 (br s, 1H), 8.4 (br s, 1H), 7.75 (d, J = 6.4 Hz, 1H), 7.23 (s, 1H), 7.12 (d, J = 6.4 Hz, 1H), 6.91(t, J = 4.0 Hz,1H);¹³C NMR (125 MHz, DMSO- d_6) δ 169.8, 158.5, 154.6, 148.6, 126.2, 126.1, 122.9, 119.8, 109.9, 109.7, 81.7, 79.5; HRMS (ESI) calcd for C₁₂H₇ClN₂O₂Na [M⁺ + Na] and [M⁺ + Na + 2] m/z 269.0094 and 271.0064, found 269.0090 and 271.0074.

Compound **5e**. Yield 0.021 g (60%, yellow solid); mp 214–218 °C; IR (KBr) 2920, 2848, 1675, 1603, 1536, 1428, 1314, 1262, 1226, 1190, 1092, 1009, 808, 767 cm⁻¹; ¹H NMR (500 MHz, DMSO- d_6) δ 13.40 (br s, 1H), 8.75–8.67 (m, 2H), 7.00 (s, 2H), 6.94–6.93 (m, 1H), 6.89–6.87 (m, 1H); ¹³C NMR (125 MHz, DMSO- d_6) δ 170.1, 158.9, 157.5, 154.6 (d, $J_{(C-F)} = 25$ Hz), 152.5, 149.7, 123.0, 114.1 (d, $J_{(C-F)} = 20$ Hz), 110.9 (d, $J_{(C-F)} = 21.8$ Hz), 110.6, 106.0, 81.1; HRMS (ESI) calcd for C₁₂H₈FN₂O₂ [M⁺ + H] *m*/*z* 231.0570, found 231.0571.

Compound **5f.** Yield 0.032 g (63%, red solid); mp 212–216 °C; IR (KBr) 3090, 2915, 1676, 1598, 1536, 1464, 1304, 1200, 1092, 953, 777 cm⁻¹; ¹H NMR (500 MHz, DMSO- d_6) δ 12.87 (br s, 1 H), 8.81 (br s, 1H), 8.37 (br s, 1H), 7.58 (d, *J* = 7.5 Hz, 1H), 7.46 (s, 1H), 7.41 (d, *J* = 8.0 Hz, 1H), 6.91 (s, 1H); ¹³C NMR (125 MHz, DMSO- d_6) δ 169.5, 154.7, 148.9, 131.7, 127.1, 120.9, 117.6, 110.1, 84.5, 81.8; HRMS (ESI) calcd for C₁₂H₈IN₂O₂ [M⁺ + H] *m*/*z* 338.9630, found 338.9623.

Compound **5***g*. Yield 0.031 g (74%, yellow solid); mp 290–294 °C; IR (KBr) 3079, 2931, 2844, 2362, 1677, 1600, 1534, 1430, 1326, 1189, 1002, 920, 789 cm⁻¹; ¹H NMR (500 MHz, DMSO-*d*₆) δ 13.10 (br s, 1H), 8.71 (br s, 2H), 7.92 (d, *J* = 7.5 Hz 1H), 7.43–7.41 (m, 2H), 7.01 (t, *J* = 5.0 Hz 1H); ¹³CNMR (125 MHz, DMSO-*d*₆) δ 169.3, 155.0, 147.2, 131.2, 126.0, 123.8, 121.2 (d, *J*_(C-F) = 30.8 Hz), 119.6, 118.2, 110.5, 105.2, 81.4, 79.1; HRMS (ESI) calcd for C₁₃H₈F₃N₂O₂ [M⁺ + H] *m*/*z* 281.0538, found 281.0537.

Compound 5h. Yield 0.032 g (82%, red solid); mp 262–266 °C; IR (KBr) 2931, 2860, 1693, 1594, 1435, 1315, 1249, 1178, 959, 855 cm⁻¹; ¹H NMR (500 MHz, DMSO- d_6) δ 12.97 (br s, 1H), 8.71 (d, *J* = 5.0 Hz, 1H), 8.18 (s, 1H), 7.84 (m, 2H), 7.55 (s, 1H), 7.37–7.31 (m, 2H), 6.92 (t, *J* = 5.0, Hz, 1H); ¹³C NMR δ 170.1, 157.2, 148.2, 130.7, 129.8, 127.9, 127.3, 126.9, 124.0, 123.5, 115.1, 109.4, 104.0, 81.1; HRMS (ESI) calcd for C₁₆H₁₁N₂O₂ [M⁺ + H] *m/z* 263.0820, found 263.0822.

Compound 5i. Yield 0.033 g (65%, red solid); mp 276–280 °C; IR (KBr) 2960, 2854, 1691, 1593, 1459, 1402, 1319, 1211, 1113, 1004, 958, 886, 772 cm⁻¹; ¹H NMR (400 MHz, DMSO- d_6) δ 13.01 (s, 1H), 8.74 (br s, 2H), 8.14–8.09 (m, 2H), 7.80–7.78 (m, 1H), 7.58 (s, 1H), 7.41 (d, *J* = 8.0 Hz,1H), 6.97–6.940 (m, 1H); ¹³C NMR (125 MHz, DMSO- d_6) δ 170.4, 155.9, 154.7, 148.9, 132.5, 130.0, 129.4, 129.0, 128.8, 126.7, 117.5, 114.6, 110.2, 104.7, 81.5; HRMS (ESI) calcd for C₁₆H₁₀BrN₂O₂ [M⁺ + H] and [M⁺ + H + 2] *m*/*z* 340.9925 and 342.9905, found 340.9926 and 342.9908.

Compound **A**.¹³ Yield 0.019 g (61%, red solid); mp 206–210 °C; IR (neat) 3096, 2915, 1676, 1593, 1536, 1443, 1293, 1200, 1077, 968, 849, 777 cm⁻¹; HRMS (ESI) calcd for $C_{12}H_9N_2O_2$ [M⁺ + H] *m/z* 213.0664, found 213.0666.

Compound **B**.¹³ Yield 0.020 g (52%, red solid); mp 230–234 °C; IR (neat) 2920, 2848, 1794, 1561, 1406, 1293, 1122, 1066, 967, 802, 678 cm⁻¹; HRMS (ESI) calcd for $C_{16}H_{11}N_2O_2$ [M⁺ + H] m/z 263.0820, found 263.0822.

Compound **7a**. Yield 0.080 g (78%, gummy liquid); IR (neat) 2957, 2905, 1758, 1567, 1505, 1463, 1257, 1092, 1014, 798 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 8.18 (s, 1H), 7.68 (m, 1H), 7.45 (d, *J* = 8.0 Hz, 1H), 7.07 (d, *J* = 8.0 Hz 1H), 7.01- 6.99 (m, 1H), 6.93 (s, 1H), 6.88 (d, *J* = 8.4 Hz, 1H), 4.94 (s, 1H), 4.19–4.10 (m, 4H), 2.34 (s, 3H), 1.19 (t, *J* = 7.2 Hz, 6H); ¹³CNMR (125 MHz) δ 168.2, 163.5, 151.7, 147.7, 139.7, 139.5, 130.0, 126.2, 122.9, 122.3, 118.6, 111.3, 61.7, 51.4, 21.2, 14.0; HRMS (ESI) calcd for C₁₉H₂₁NO₅Na [M⁺ + Na] *m/z* 366.1318, found 366.1316.

Compound 7b. Yield 0.092 g (75%, gummy liquid); IR (neat) 3054, 2987, 1737, 1567, 1422, 1324, 1148, 1019, 683 cm⁻¹; ¹H NMR (500 MHz) δ 8.15 (dd, *J* = 5.0 and 4.5 Hz, 1H), 7.79 (d, *J* = 8.0 Hz, 1H), 7.69–7.66 (m, 1H), 7.58 (d, *J* = 8.1 Hz, 2H), 7.22 (d, *J* = 7.9 Hz, 2H), 7.04–7.00 (m, 2H), 6.82 (s, 1H), 6.76 (d, *J* = 8.5 Hz, 1H), 5.65 (s, 1H), 4.20–4.09 (m, 2H), 2.33 (s, 3H), 1.17 (t, *J* = 7.0 Hz, 3H); ¹³C NMR (100 MHz) δ 164.6, 162.9, 152.7, 147.7, 141.4, 139.6, 137.7, 134.0,130.9, 129.6, 128.7, 125.8, 121.5, 119.1, 117.3, 111.8, 67.3, 62.4, 21.4, 13.9; HRMS (ESI) calcd for C₂₂H₂₁NO₅SNa [M⁺ + Na] *m*/*z* 434.1030, found 434.1034.

Compound 7c. Yield 0.093 g (73%, gummy liquid); IR (neat) 3060, 2926, 1742, 1572, 1422, 1329, 1148, 1019, 812, 657 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 8.15 (s, 1H), 7.78 (d, *J* = 8.5 Hz, 1H), 7.69–7.66 (m, 1H), 7.58 (d, *J* = 8.0 Hz, 2H), 7.22 (d, *J* = 8.0 Hz, 2H), 7.04–7.01 (m, 2H), 6.84 (s, 1H), 6.77 (d, *J* = 8.0 Hz, 1H), 5.64 (s, 1H), 4.18–4.12 (m, 2H), 2,42 (s, 3H), 2.33 (s, 3H), 1.18 (t, *J* = 7.0 Hz, 3H); ¹³CNMR (100 MHz) δ 164.7, 163.0, 152.7, 147.7, 145.0, 141.3, 139.6, 134.8, 130.9, 129.7, 129.3, 125.8, 121.5, 119.0, 117.5, 111.8, 67.2, 62.4, 21.7, 21.5, 13.9; HRMS (ESI) calcd for C₂₃H₂₄NO₅S [M⁺ + H] *m/z* 426.1375, found 426.1378.

Compound **8** [Method iii(a) Was Used]. Yield 0.025 g (74%, red solid); mp 182–186 °C; IR (neat) 2915, 2848, 1681, 1646, 1595, 1435, 1333, 1228, 1108, 964, 785 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 13.70 (s, 1H), 7.73 (s, 1H), 7.65 (d, *J* = 7.5 Hz, 1H), 7.48 (d, *J* = 9.0 Hz, 1H), 7.26 (d, *J* = 7.5 Hz, 1H), 7.03 (s, 1H), 6.97 (d, *J* = 7.5 Hz, 1H), 6.64 (t, *J* = 6.0 Hz, 1H), 2.42 (s, 3H); ¹³C NMR (125 MHz, CDCl₃) δ 171.5, 149.4, 148.8, 139.6, 135.2, 131.8, 123.5, 119.0, 116.3, 111.7, 110.7, 81.8, 21.5; HRMS (ESI) calcd for C₁₄H₁₂NO₂ [M⁺ + H] *m*/*z* 226.0868, found 226.0867.

Compound **9** [Method iii(b) Was Used]. Yield 0.098 g (82%, red solid); mp 120–124 °C; IR (neat) 2923, 2831, 1675, 1623, 1512, 1396, 1269, 1164, 1107, 932, 762 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 7.92 (d, *J* = 8.5 Hz, 1H), 7.75 (d, *J* = 6.5 Hz, 1H), 7.57 (t, *J* = 7.0 Hz, 1H), 7.17 (d, *J* = 8.0 Hz, 1H), 6.98 (s, 1H), 6.89–6.83 (m, 2H), 4.08 (s, 3H), 2.40 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 166.8, 153.3, 149.5, 141.5, 136.9, 131.5, 126.6, 126.3, 122.5, 115.7, 114.4, 110.3, 82.9, 46.8, 21.5; HRMS (ESI) calcd for C₁₅H₁₃NO₂Na [M⁺ + Na] *m*/*z* 262.0844, found 262.0845.

Crystal Data. Compound **3m.** $C_{21}H_{20}N_2O_5$, M = 380.39, Monoclinic, Space group C2/c, a = 16.953(2), b = 10.6145(14), c = 22.394(3) Å, V = 3827.2(8) Å³, $\alpha = 90$, $\beta = 108.248(5)$, $\gamma = 90$, Z = 8, $\mu = 0.095$ mm⁻¹, data/restraints/parameters: 4431/0/255, *R* indices ($I > 2\sigma(I)$): R1 = 0.0582, wR2 (all data) = 0.1802. CCDC No. 1511133.

Compound **5a**. $C_{13}H_{10}N_2O_2$, M = 226.23, Monoclinic, Space group C2/c, a = 23.0446(19), b = 6.2463(5), c = 15.0567(12) Å, V = 2138.3(3) Å³, $\alpha = 90$, $\beta = 93.350(4)$, $\gamma = 90$, Z = 8, $\mu = 0.097$ mm⁻¹, data/restraints/ parameters: 1872/0/159, R indices ($I > 2\sigma(I)$): R1 = 0.0379, *w*R2 (all data) = 0.1063. CCDC No. 1511134.

Compound **9.** $C_{15}H_{13}NO_2$, M = 239.26, Monoclinic, Space group C2/c, a = 25.879(2), b = 7.4025(6), c = 13.146(1) Å, V = 2514.0(4) Å³, $\beta = 93.350(4)$, Z = 8, $\mu = 0.084$ mm⁻¹, data/restraints/parameters: 2190/0/165, R indices ($I > 2\sigma(I)$): R1 = 0.0658, wR2 (all data) = 0.1820. CCDC No. 1525099.

ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.joc.6b02693.

Figures giving ORTEP drawings as shown by X-ray crystallography, and copies of ¹H/¹³C NMR spectra of all new products (PDF) Crystal data (CIF)

AUTHOR INFORMATION

Corresponding Author

*E-mail: kckssc@uohyd.ac.in; kckssc@yahoo.com.

The Journal of Organic Chemistry

ORCID 🔍

K. C. Kumara Swamy: 0000-0002-7617-706X

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

We thank Department of Science & Technology (DST, New Delhi) for financial support, single crystal X-ray diffractometer and HRMS facility under FIST, IRHPA and PURSE programmes. We also thank UGC (New Delhi) for the UPE programme. KCK thanks DST for the J. C. Bose fellowship (No. SR/S2/JCB-53/2010). ASR thanks CSIR (New Delhi) for a fellowship.

REFERENCES

(1) (a) Tyman, J. H. P. *Synthetic and Natural Phenols*; Elsevier: New York, 1996. (b) Rappoport, Z. *The Chemistry of Phenols*; Wiley-VCH: Weinheim, 2003.

(2) (a) Yu, Z.; Ma, B.; Chen, M.; Wu, H.-H.; Liu, L.; Zhang, J. J. Am. Chem. Soc. 2014, 136, 6904. (b) Takise, R.; Muto, K.; Yamaguchi, J.; Itami, K. Angew. Chem., Int. Ed. 2014, 53, 6791. (c) Correa, A.; Martin, R. J. Am. Chem. Soc. 2014, 136, 7253. (d) Hao, X.-Q.; Chen, L.-J.; Ren, B.; Li, L.-Y.; Yang, X.-Y.; Gong, J.-F.; Niu, J.-L.; Song, M.-P. Org. Lett. 2014, 16, 1104. (e) Sharma, U.; Naveen, T.; Maji, A.; Manna, S.; Maiti, D. Angew. Chem., Int. Ed. 2013, 52, 12669. (f) Agrawal, T.; Cook, S. P. Org. Lett. 2014, 16, 5080. (g) Wu, Z.; Luo, F.; Chen, S.; Li, Z.; Xiang, H.; Zhou, X. Chem. Commun. 2013, 49, 7653. (h) Roger, J.; Doucet, H. Org. Biomol. Chem. 2008, 6, 169. (i) Quasdorf, K. W.; Antoft-Finch, A.; Liu, P.; Silberstein, A. L.; Komaromi, A.; Blackburn, T.; Ramgren, S. D.; Houk, K. N.; Snieckus, V.; Garg, N. K. J. Am. Chem. Soc. 2011, 133, 6352. (3) (a) Smith, F. J.; Lewis, N. L. J. Am. Chem. Soc. 1986, 108, 2728. (b) Xiao, B.; Gong, T.-J.; Liu, Z.-J.; Liu, J.-H.; Luo, D.-F.; Xu, J.; Liu, L. J. Am. Chem. Soc. 2011, 133, 9250. (c) Luo, S.; Luo, F.-X.; Zhang, X.-S.; Shi, Z.-J. Angew. Chem., Int. Ed. 2013, 52, 10598. (d) Patra, T.; Bag, S.; Kancherla, R.; Mondal, A.; Dey, A.; Pimparkar, S.; Agasti, S.; Modak, A.; Maiti, D. Angew. Chem., Int. Ed. 2016, 55, 7751. (e) Duan, S.; Xu, Y.; Zhang, X.; Fan, X. Chem. Commun. 2016, 52, 10529.

(4) (a) Boebel, T. A.; Hartwig, J. F. J. Am. Chem. Soc. 2008, 130, 7534.
(b) Huang, C.; Gevorgyan, V. J. Am. Chem. Soc. 2009, 131, 10844.
(c) Huang, C.; Chattopadhyay, B.; Gevorgyan, V. J. Am. Chem. Soc. 2011, 133, 12406. (d) Huang, C.; Ghavtadze, N.; Chattopadhyay, B.; Gevorgyan, V. J. Am. Chem. Soc. 2011, 133, 17630.

(5) Xiao, B.; Fu, Y.; Xu, J.; Gong, T.-J.; Dai, J.-J.; Yi, J.; Liu, L. J. Am. Chem. Soc. **2010**, 132, 468.

(6) (a) Zhao, X.; Yeung, C. S.; Dong, V. M. J. Am. Chem. Soc. **2010**, 132, 5837. (b) John, A.; Nicholas, K. M. J. Org. Chem. **2012**, 77, 5600. (c) Gong, T.-J.; Xiao, B.; Liu, Z.-J.; Wan, J.; Xu, J.; Dong-Fen Luo, D.-F.; Fu, Y.; Liu, L. Org. Lett. **2011**, 13, 3235.

(7) (a) Yao, J.; Feng, R.; Wu, Z.; Liu, Z.; Zhang, Y. Adv. Synth. Catal.
2013, 355, 1517. (b) Raghuvanshi, K.; Rauch, K.; Ackermann, L. Chem. -Eur. J. 2015, 21, 1790. (c) Borah, A. J.; Yan, G.; Wang, L. Eur. J. Org. Chem. 2015, 2015, 4782. (d) Liang Wang, L.; Pan, L.; Huang, Y.; Chen, Q.; He, M. Eur. J. Org. Chem. 2016, 2016, 3113. (e) Zhang, W.; Zhang, J.; Ren, S.; Liu, Y. J. Org. Chem. 2014, 79, 11508. (f) Xu, Y.; Liu, P.; Li, S.-L.; Sun, P. J. Org. Chem. 2015, 80, 1269. (g) Liu, B.; Jiang, H.-Z.; Shi, B.-F. J. Org. Chem. 2014, 79, 1521.

(8) Gu, S.; Chen, C.; Chen, W. J. Org. Chem. 2009, 74, 7203.

(9) (a) Chan, W.-W.; Lo, S.-F.; Zhou, Z.; Yu, W.-Y. J. Am. Chem. Soc.
2012, 134, 13565. (b) Hyster, T. K.; Ruhl, K. E.; Rovis, T. J. Am. Chem. Soc.
2013, 135, 5364. (c) Shi, Z.; Koester, D. C.; Boultadakis-Arapinis, M.; Glorius, F. J. Am. Chem. Soc. 2013, 135, 12204. (d) Liang, Y.; Yu, K.; Li, B.; Xu, S.; Song, H.; Wang, B. Chem. Commun. 2014, 50, 6130.
(e) Shi, L.; Yu, K.; Wang, B. Chem. Commun. 2015, 51, 17277.
(f) Dateer, R. B.; Chang, S. Org. Lett. 2016, 18, 68. (g) Ai, W.; Yang, X.; Wu, Y.; Wang, X.; Li, Y.; Yang, Y.; Zhou, B. Chem. - Eur. J. 2014, 20, 17653. (h) Yang, Y.; Wang, X.; Li, Y.; Zhou, B. Angew. Chem., Int. Ed.
2015, 54, 15400. (i) Chen, X.; Hu, X.; Bai, S.; Deng, Y.; Jiang, H.; Zeng,

W. Org. Lett. 2016, 18, 192. (j) Das, D.; Biswas, A.; Karmakar, U.; Chand, S.; Samanta, R. J. Org. Chem. 2016, 81, 842. (k) Bai, P.; Huang, X.-F.; Xu, G.-D.; Huang, Z.-Z. Org. Lett. 2016, 18, 3058. (l) Hu, F.; Xia, Y.; Ma, C.; Zhang, Y.; Wang, J. Chem. Commun. 2015, 51, 7986.

(10) (a) Xia, Y.; Liu, Z.; Feng, S.; Zhang, Y.; Wang, J. J. Org. Chem. 2015, 80, 223. (b) Phatake, R. S.; Patel, P.; Ramana, C. V. Org. Lett. 2016, 18, 2828.

(11) (a) Zhao, D.; Kim, J. H.; Stegemann, L.; Strassert, C. A.; Glorius, F. Angew. Chem., Int. Ed. **2015**, *54*, 4508. (b) Li, J.; Tang, M.; Zang, L.; Zhang, X.; Zhang, Z.; Ackermann, L. Org. Lett. **2016**, *18*, 2742. (c) Liu, X.-G.; Zhang, S.-S.; Wu, J.-Q.; Li, Q.; Wang, H. Tetrahedron Lett. **2015**, *56*, 4093.

(12) (a) Rama Suresh, R.; Kumara Swamy, K. C. J. Org. Chem. 2012, 77, 6959. (b) Allu, S.; Kumara Swamy, K. C. J. Org. Chem. 2014, 79, 3963.
(c) Tulichala, R. N. P.; Kumara Swamy, K. C. Chem. Commun. 2015, 51, 12008. (d) Allu, S.; Kumara Swamy, K. C. Adv. Synth. Catal. 2015, 357, 2665. (e) Allu, S.; Kumara Swamy, K. C. RSC Adv. 2015, 5, 92045. (f) Allu, S.; Ravi, M.; Kumara Swamy, K. C. Eur. J. Org. Chem. 2016, 34, 5697.

(13) In a few cases (e.g., **5c** and **A**–**B**), although TLC indicated a pure product, we were not able to get good line-like $^{13}\mathrm{C}/^{1}\mathrm{H}$ spectra. However, the HRMS data were clear-cut. It is possible that these compounds show tautomeric behavior, but we have not investigated this in the current work.

(14) (a) Chao, H.; Turdi, H.; Herpin, T. F.; Roberge, J. Y.; Liu, Y.; Schnur, D. M.; Poss, M. A.; Rehfuss, R.; Hua, J.; Wu, Q.; Price, L. A.; Abell, L. M.; Schumacher, W. A.; Bostwick, J. S.; Steinbacher, T. E.; Stewart, A. B.; Ogletree, M. L.; Huang, C. S.; Chang, M.; Cacace, A. M.; Arcuri, M. J.; Celani, D.; Wexler, R. R.; Lawrence, R. M. J. Med. Chem. **2013**, *56*, 1704. (b) Song, X. Y.; Chen, W. M.; Lin, L.; Ruiz, C. H.; Cameron, M. D.; Duckett, D. R.; Kamenecka, T. M. *Bioorg. Med. Chem. Lett.* **2011**, *21*, 7072.

(15) Perrin, D. D.; Armarego, W. L. F.; Perrin, D. Purification of Laboratory Chemicals; Pergamon: Oxford U.K., 1986.

(16) (a) Sheldrick, G. M. SADABS, Siemens Area Detector Absorption Correction; University of Göttingen: Göttingen, Germany, 1996.
(b) Sheldrick, G. M. SHELX-97, A Program for Crystal Structure Solution and Refinement; University of Göttingen: Göttingen, Germany, 1997.
(c) Sheldrick, G. M. SHELXTL NT Crystal Structure Analysis Package, version 5.10; Bruker AXS, Analytical X-ray System: Madison, WI, 1999.
(17) Chan, W.-W.; Yeung, S.-H.; Zhou, Z.; Chan, A. S. C.; Yu, W.-Y.

Org. Lett. 2010, 12, 604.

(18) Pastine, S. J.; Gribkov, D. V.; Sames, D. J. Am. Chem. Soc. 2006, 128, 14220.

(19) Pawar, G. G.; Brahmanandan, A.; Kapur, M. Org. Lett. 2016, 18, 448.